What is HC Wainwright’s Estimate for VERV FY2025 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV) – Research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Verve Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.16) per share for the year, up from their prior estimate of ($2.38). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Verve Therapeutics’ Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.70) EPS.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.36. The company had revenue of $32.98 million for the quarter, compared to analysts’ expectations of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%.

Several other analysts have also recently commented on the stock. Canaccord Genuity Group boosted their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, April 15th. Guggenheim boosted their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, April 15th. Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Finally, Cantor Fitzgerald upgraded shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Verve Therapeutics has a consensus rating of “Buy” and an average target price of $25.75.

Verve Therapeutics Stock Down 8.2%

Shares of VERV stock opened at $4.23 on Wednesday. The stock has a market cap of $377.07 million, a P/E ratio of -1.72 and a beta of 1.82. Verve Therapeutics has a 52 week low of $2.86 and a 52 week high of $9.31. The company’s fifty day simple moving average is $4.68 and its two-hundred day simple moving average is $5.83.

Institutional Trading of Verve Therapeutics

Several hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC raised its position in shares of Verve Therapeutics by 126.2% during the 1st quarter. Acadian Asset Management LLC now owns 30,803 shares of the company’s stock valued at $140,000 after buying an additional 17,186 shares in the last quarter. Woodline Partners LP purchased a new stake in shares of Verve Therapeutics during the 1st quarter valued at about $12,648,000. Goldman Sachs Group Inc. raised its position in shares of Verve Therapeutics by 90.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,413,118 shares of the company’s stock valued at $6,458,000 after buying an additional 671,939 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Verve Therapeutics by 1,028.7% during the 1st quarter. AQR Capital Management LLC now owns 373,207 shares of the company’s stock valued at $1,706,000 after buying an additional 340,143 shares in the last quarter. Finally, Alpine Global Management LLC purchased a new stake in shares of Verve Therapeutics during the 1st quarter valued at about $57,000. 97.11% of the stock is currently owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.